World Health Organization Issues Concern Over Acute Shortage of Obesity Injections
Under 10% of individuals eligible to benefit from weight-loss injections including Wegovy have access to them, states the global health agency as it issues its inaugural advice on the therapies.
Considering in excess of 1,000,000,000 people worldwide currently living with obesity, it is calling for more widespread and fairer availability to GLP-1 medication.
According to projections, more than two billion could be obese by 2030 unless action is taken.
"The latest guidance affirms that obesity is a long-term condition that can be managed with comprehensive and continuous care," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are significant hurdles to broad availability to the treatments that can help people shift considerable body mass, explains the agency.
GLP-1 Therapy Supply Crisis
Despite the current most optimistic case, the supply of such drugs would only suffice for around 100 million people – under 10% of eligible patients, according to the WHO.
The guideline urges countries and companies to increase availability, by measures including licensing agreements.
A patent on a key compound – the main component of the drug Wegovy – is set to lapse in multiple countries in 2026.
How Weight-Loss Jabs Function
The injections mimick a body's own hormone to delay gastric emptying, curb appetite and boost the sense of being full so people eat less.
Individuals commonly see weight reduction within a few weeks of beginning the once-weekly jabs.
Studies indicates patients may regain a significant portion after a year of halting the drug, when their typical food cravings resume.
To be overweight or obese elevates your chance for contracting health problems, such as type 2 diabetes, heart disease, brain attack, and certain cancers.
Obesity impacts people in every country and was responsible for millions of deaths worldwide in 2024, according to the WHO.
